| Date | Title | | | 12/06/18 | Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response| Study Demonstrates Utility of Assay in Neoadjuvant and Adjuvant Treatment Settings
SAN CARLOS, Calif., Dec. 6, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, presented data from two studies this week at the 2018 San Antonio Breast Cancer Symposium (SABCS), demonstrating the ability of its Signatera™ RUO (research-use-only) circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD) up to two ye... |
| | | 11/29/18 | Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study| Primary study results on the 20,000 patients anticipated in 2019 to validate the clinical utility of routine screening for microdeletion genetic conditions
SAN CARLOS, Calif., Nov. 29, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has enrolled 20,000 patients in the SMART (SNP-based Microdeletion and Aneuploidy Registry Trial) study, designed to evaluate the clinical utility of the company's Panorama® non-invasive prenata... |
| | | 11/28/18 | Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test| Represents a Key Milestone Towards Achieving Medicare Reimbursement
SAN CARLOS, Calif., Nov. 28, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for the company's kidney transplant rejection assay, representing a key reimbursement milestone in preparation for the commercialization of its CLIA-certified lab developed test in 2019.
"We are pleased with this progres... |
| | | 11/08/18 | Natera Reports Third Quarter 2018 Financial Results| SAN CARLOS, Calif., Nov. 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2018, and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $65.3 million in the third quarter of 2018 compared to $55.9 million in the third quarter o... |
| | | 11/01/18 | Natera Announces Third Quarter 2018 Earnings Conference Call| SAN CARLOS, Calif., Nov. 1, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended Sept. 30, 2018, after the market close on Nov. 8, 2018. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook.
Earnings Con... |
| | | 10/18/18 | Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine| Combines Neon's Personal Neoantigen Vaccine and Signatera (RUO) Circulating Tumor DNA Biomarker in Metastatic Non-Small Cell Lung Cancer Trial
SAN CARLOS, Calif., & CAMBRIDGE, Mass., Oct. 18, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and Neon Therapeutics, Inc. (NASDAQ: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced a research collaboration using Natera's Signatera™ (RUO) circula... |
| | | 09/13/18 | Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera™ ctDNA Assay as a Potential Biomarker for Opdivo (nivolumab) in a Prospective Phase 2 Adjuvant Non-Small Cell Lung Cancer Clinical Trial| First Study Using ctDNA-based Minimal Residual Disease Assessment for Immunotherapy in the Adjuvant NSCLC Setting
SAN CARLOS, Calif., Sept. 13, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera's Signatera™ custom circulating tumor DNA (ctDNA) assay in a Phase 2 study in the adjuvant non-small cell lung cancer (NSCLC) setting.
The study will use ... |
| | | 08/15/18 | Natera and Fox Chase Cancer Center to Collaborate on Kidney Cancer Study| SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company's Signatera™ (Research-Use Only) customized circulating tumor DNA (ctDNA) assay for recurrence monitoring of kidney cancer.
The study will analyze biological specimens collected and banked from 49 patients diagnosed wit... |
| | | 08/08/18 | Natera Reports Second Quarter 2018 Financial Results| SAN CARLOS, Calif., Aug. 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2018 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $63.1 million in the second quarter of 2018 compared to $52.3 million in the second quarter of ... |
| | | 08/07/18 | Natera Clinical Study Validates New Biomarker for Aneuploidy and Adverse Pregnancy Outcomes| Study Highlights Proprietary Technology for Fetal Fraction Measurement in Non-Invasive Prenatal Testing
SAN CARLOS, Calif., Aug. 7, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced new study results demonstrating that fetal fraction, as measured by Panorama® non-invasive prenatal testing (NIPT), can be used as an independent biomarker to screen for certain chromosome abnormalities and adverse pregnancy outcomes. Fetal fraction is th... |
| | | 08/02/18 | Study Shows Natera's Spectrum Preimplantation Genetic Testing for Aneuploidy Improves IVF Outcomes for All Women, Regardless of Maternal Age| SAN CARLOS, Calif., Aug. 2, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the publication of a study demonstrating the value of the company's Spectrum® preimplantation genetic screening for aneuploidy (PGT-A) to improve in vitro fertilization (IVF) results for all women, including those of advanced maternal age.
The study, published in Fertility and Sterility, retrospectively analyzed pregnancy ou... |
| | | 08/01/18 | Natera, Inc. Announces Second Quarter 2018 Earnings Conference Call| SAN CARLOS, Calif., Aug. 1, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, 2018, after the market close on Aug. 8, 2018. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook.
Earnings Conference Call Inform... |
| | | 07/31/18 | Natera Appoints Roy Baynes to Board of Directors, Adding Deep Oncology Experience| SAN CARLOS, Calif., July 31, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, has appointed Roy Baynes, MB.BCh., M.Med., PhD, FCP, FACP, Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories, to its board of directors effective July 25, 2018.
Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at G... |
| | | 07/12/18 | Natera Announces Pricing of Follow-On Offering| SAN CARLOS, Calif., July 12, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $20.00 per share. Closing of the offering is expected to occur on July 16, 2018, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up... |
| | | 07/10/18 | Natera Launches Proposed Follow-On Offering| SAN CARLOS, Calif., July 10, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the launch of a proposed follow-on public offering of $75,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock from Natera at the public offering price less the underwriting discount. The... |
| | | 06/21/18 | Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology| Commercializing Core Cell-free DNA Technology Beyond Reproductive Health
SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, will share data and roadmap for its emerging businesses in renal transplantation and oncology, during an investor call on June 27, 2018.
Date:
June 27, 2018
Time:
1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In US/Canada:
(877) 823... |
| | | 06/21/18 | Natera Develops Powerful Kidney Transplant Rejection Biomarker| Data to be Presented at The Transplantation Society International Congress in Madrid on July 3, 2018
SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA analysis, announces a powerful new kidney transplant rejection biomarker and study results in collaboration with the University of California, San Francisco, a recognized leader in transplantation care. The data demonstrates superior performance of its massively-multiplexed PCR (mmPCR) te... |
| | | 06/19/18 | Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer| Signatera assay to be used in research to evaluate treatment response and minimal residual disease
SAN CARLOS, Calif., June 19, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a research collaboration with the Institut Jules Bordet, an internationally renowned multidisciplinary cancer reference center in Belgium, using the company's Signatera™ research-use-only (RUO) circulating tumor DNA (ctDNA) assay to evaluate molecular respon... |
| | | 06/13/18 | Natera Announces New Clinical Utility Data and Issuance of CPT Code for NIPT in Twin Pregnancies| Unique Twin Zygosity Test Adds Clinical Value in Over 1 in 4 Cases
SAN CARLOS, Calif., June 13, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, announces that the American Medical Association has issued a new CPT code for zygosity testing in twin pregnancies. Zygosity refers to whether twins are identical (mono-zygotic) or non-identical (di-zygotic) and is closely linked with risks for placental disorders that can occur in identical twin p... |
| | | 05/08/18 | Natera Reports First Quarter 2018 Financial Results| SAN CARLOS, Calif., May 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2018, and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $62.3 million in the first quarter of 2018 compared to $49.4 million in the first quarter of 20... |
| | | 05/01/18 | Natera Inc. Announces First Quarter 2018 Earnings Conference Call| SAN CARLOS, Calif., May 1, 2018 /PRNewswire/ -- Natera, (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2018, after the market close on May 8, 2018. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook.
Earnings Conference Call Information:
... |
| | | 04/13/18 | Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies| Performance Data for Treatment Monitoring, Recurrence Monitoring, and Staging at Diagnosis
SAN CARLOS, Calif., April 13, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will present data demonstrating the ability of Signatera™ (Research Use Only) to monitor treatment response, detect minimal residual disease, and identify disease recurrence in bladder and colorectal cancers at the AACR (American Association ... |
| | | 04/10/18 | Natera To Present New Data at ACMG Annual Meeting| Study results demonstrate value of SNP-based non-invasive prenatal testing, expanded carrier screening, and embryo and miscarriage tissue testing across various genetic conditions
SAN CARLOS, Calif., April 10, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will present new data that demonstrate the value of its unique single nucleotide polymorphism (SNP)-based technology and the benefits of expanded carrier... |
| | | 04/09/18 | Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer| Leading authority on genomics and diagnostics in medical practice will help Natera's efforts in advancing individualized genomic medicine
SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA (cfDNA), has appointed Paul R. Billings, M.D., Ph.D., as Chief Medical Officer and Senior Vice-President of Medical Affairs to help lead its efforts across reproductive health, oncology, and new em... |
| | | 03/13/18 | Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results| SAN CARLOS, Calif., March 13, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Signed $50.0 million next-generation sequencing agreement with QIAGEN, Inc, with $40.0 million cash r... |
| | | 03/12/18 | QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN's GeneReader NGS System| HILDEN, Germany, and SAN CARLOS, Calif., March 12, 2018 /PRNewswire/ -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge, cell-free DNA assays for use on QIAGEN's GeneReader NGS Sys... |
| | | 03/07/18 | Natera Inc. Announces Fourth Quarter and Fiscal 2017 Earnings Conference Call| Natera Also Presenting at the 38th Annual Cowen Healthcare Conference
SAN CARLOS, Calif., March 7, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2017 after the market close on March 13, 2018. Natera will host a conference call and webcast at 2 p.m. PT (5 p.m. ET) to discuss its financial results, business... |
| | | 03/05/18 | Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System| SAN CARLOS, Calif., March 5, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Yale New Haven Health has fully integrated the company's Panorama® non-invasive prenatal test (NIPT) and Horizon™ carrier screening test into its Epic electronic medical record (EMR) platform, making it easier for physicians to order and receive prenatal genetic testing information.
... |
| | | 01/29/18 | Natera To Feature Expanded Panorama® Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting| SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded Panorama® non-invasive prenatal test (NIPT), which is now validated for screening twin pregnancies, at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in Dallas, Jan. 29 to Feb. 3, 2018 (booth No. 161).
Panorama® is the first NIPT that can screen twin p... |
| | | 01/08/18 | Natera To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018| SAN CARLOS, Calif., Jan. 8, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will webcast a live presentation at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, Jan. 11, 2018 at 9:00 a.m. Pacific Time.
Natera CEO Matthew Rabinowitz will provide an overview of the company and its latest devel... |
| |
|
